Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
"ALRV5XR was designed to target various of the multiple underlying physiological causes of hair loss. The agent is a formulation of standardised botanical extracts, vitamins, and minerals that can be delivered both systemically, as a supplement, or topically, as a shampoo, conditioner, or follicle serum."
"Results from published clinical trials and meta-analyses of current standard therapy showed that 48 weeks of treatment resulted in average gains of hair density of 11·5 THs/cm2 for 2% minoxidil, 14·9 THs/cm2 for 5% minoxidil, and 14·8 THs/cm2 for 1 mg finasteride. The efficacy of ALRV5XR reported in this study displays clear superiority over those results. Indeed, after 12 weeks, ALRV5XR's efficacy of 10·9 THs/cm2 reaches 73 to 94% of the 48 week efficacy of standard therapy. At 24 weeks and with an efficacy of 21·0 THs/cm2, ALRV5XR reached gains that are 141 to 182% of those corresponding to the efficacy established for standard therapies at 48 weeks. Longer-term studies are needed to further confirm the apparent linear progression of the linear effect of ALRV5XR treatment. The current results suggest that TH regrowth to more than 40 THs/cm2 over 48 weeks may be possible."
This is another "natural" scam isn't it? Sample size is a meager 46 participants. Not only that but when you break down the effects in the trimodal response group, it doesn't sound as convincing.
"By week 24, the TH density response profile of the ALRV5XR treated group displayed a trimodal distribution of hair regrowth response, with 45·5% of the group behaving as low responders (0–5 THs/cm2), 36·4% as moderate responders (10–20 THs/cm2), and 18·2% as high responders (> 25 THs/cm2). Nevertheless, when evaluated on a percentage basis at 24 weeks, all ALRV5XR subjects were more uniformly distributed. This response pattern suggests that approximately 45% of the ALRV5XR subjects will at least maintain their baseline TH while mildly improving their TH density. Of note, approximately 55% of men will have important favourable responses, regardless of individual characteristics. In clear contrast, 50% and 81·8% of the placebo group subjects decreased their TH density at weeks 12 and 24, respectively."
"ALRV5XR was designed to target various of the multiple underlying physiological causes of hair loss. The agent is a formulation of standardised botanical extracts, vitamins, and minerals that can be delivered both systemically, as a supplement, or topically, as a shampoo, conditioner, or follicle serum."
"Results from published clinical trials and meta-analyses of current standard therapy showed that 48 weeks of treatment resulted in average gains of hair density of 11·5 THs/cm2 for 2% minoxidil, 14·9 THs/cm2 for 5% minoxidil, and 14·8 THs/cm2 for 1 mg finasteride. The efficacy of ALRV5XR reported in this study displays clear superiority over those results. Indeed, after 12 weeks, ALRV5XR's efficacy of 10·9 THs/cm2 reaches 73 to 94% of the 48 week efficacy of standard therapy. At 24 weeks and with an efficacy of 21·0 THs/cm2, ALRV5XR reached gains that are 141 to 182% of those corresponding to the efficacy established for standard therapies at 48 weeks. Longer-term studies are needed to further confirm the apparent linear progression of the linear effect of ALRV5XR treatment. The current results suggest that TH regrowth to more than 40 THs/cm2 over 48 weeks may be possible."
This is another "natural" scam isn't it? Sample size is a meager 46 participants. Not only that but when you break down the effects in the trimodal response group, it doesn't sound as convincing.
"By week 24, the TH density response profile of the ALRV5XR treated group displayed a trimodal distribution of hair regrowth response, with 45·5% of the group behaving as low responders (0–5 THs/cm2), 36·4% as moderate responders (10–20 THs/cm2), and 18·2% as high responders (> 25 THs/cm2). Nevertheless, when evaluated on a percentage basis at 24 weeks, all ALRV5XR subjects were more uniformly distributed. This response pattern suggests that approximately 45% of the ALRV5XR subjects will at least maintain their baseline TH while mildly improving their TH density. Of note, approximately 55% of men will have important favourable responses, regardless of individual characteristics. In clear contrast, 50% and 81·8% of the placebo group subjects decreased their TH density at weeks 12 and 24, respectively."
Last edited: